Acadia Pharmaceuticals (ACAD) Interest Expenses (2018 - 2019)
Acadia Pharmaceuticals' quarterly Interest Expenses came in at $12000.0 in Q2 2019, down 95.14% year-on-year from $247000.0 in Q2 2018, and down 94.76% quarter-over-quarter from $229000.0 in Q1 2019.
Acadia Pharmaceuticals has reported Interest Expenses for 2 years, with the latest figure at $12000.0 in Q2 2019.
- For the quarter ending Q2 2019, Interest Expenses fell 95.14% year-over-year to $12000.0; the trailing twelve-month figure through Mar 2020 stood at $12000.0 (down 99.42% YoY), and the FY2018 full-year result was $1.8 million, changed N/A from the prior year.
- Interest Expenses for Q2 2019 stood at $12000.0, down from $229000.0 in the prior quarter.
- The five-year high for Interest Expenses was $1.7 million in Q3 2018, with the low at -$127000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 12,000.00 |
| Jun 30, 2019 | 12,000.00 |
| Mar 31, 2019 | 229,000.00 |
| Mar 31, 2019 | 229,000.00 |
| Dec 31, 2018 | -127,000.00 |
| Dec 31, 2018 | -127,000.00 |
| Sep 30, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.72 Mn |
| Jun 30, 2018 | 247,000.00 |
| Jun 30, 2018 | 247,000.00 |